Bolden Therapeutics

4:00 PM - 4:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Bolden Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapeutics to treat central nervous system diseases by stimulating the endogenous formation of new brain cells. Bolden’s research has demonstrated enhanced neurogenesis in mice via targeting a novel signaling pathway, and the company has multiple antisense oligonucleotide candidates in preclinical study. Our target clinical indications include neurodegenerative conditions (e.g., Alzheimer’s disease), mood disorders (e.g., treatment resistant depression) and brain injury (including recovery from stroke). Bolden’s scientific underpinnings come from the laboratories of Drs Justin Fallon and Ashley Webb, both professors of Neuroscience and Molecular Biology respectively at Brown University.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
2'MOE exon-skipping antisense oligonucleotide to promote neurogenesis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Co-founder and CEO
Bolden Therapeutics